SCHEMBL4939209

SCHEMBL4939209

CCOC(=O)c1[nH]c(=O)c(O)c2c1CCN(Cc1ccc(F)c(Cl)c1)C2=O

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PDE3B Q13370 3/20 0.39
PDE3A Q14432 3/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
EZH2 Q15910 4/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
BRD4 O60885 1/20 0.36
MDM2 Q00987 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484368 0.91 MEN1 (0.39) ALDH1A1MEN1KMT2APDE3BPDE3A
SCHEMBL2733763 0.87 AKR1B1 (0.41) EZH2
SCHEMBL10232283 0.86 GPR52 (0.38) EZH2
SCHEMBL4487029 0.85 AKR1B1 (0.36) EZH2
SCHEMBL16978652 0.85 ALDH1A1 (0.47) ALDH1A1MEN1KMT2APDE3BPDE3A
SCHEMBL4473406 0.83 ALDH1A1 (0.42) ALDH1A1MEN1KMT2APDE3BPDE3A
SCHEMBL2730844 0.81 PARP1 (0.34)
SCHEMBL16982800 0.81 EZH2 (0.35) EZH2
SCHEMBL4478453 0.81 DAO (0.39) ALDH1A1LMNAHTTSMN1; SMN2L3MBTL1
SCHEMBL1336916 0.80 MEN1 (0.42) ALDH1A1MEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150218164-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. 2015-08-06 US disclosed
US-20150218164-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. 2015-08-06 US disclosed
US-20080280945-A1 Crystalline forms of an HIV integrase inhibitor MERCK SHARP & DOHME CORP. 2008-11-13 US disclosed
US-20080280945-A1 Crystalline forms of an HIV integrase inhibitor MERCK SHARP & DOHME CORP. 2008-11-13 US disclosed
US-20080280945-A1 Crystalline forms of an HIV integrase inhibitor MERCK SHARP & DOHME CORP. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280945-A1 Crystalline forms of an HIV integrase inhibitor TYMP, SAMHD1, ACIN1 ALDH1A1 3635/4885MEN1 3927/4885KMT2A 3173/4885
US-20150218164-A1 SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS HIV INTEGRASE INHIBITORS SAMHD1, ENTPD5, DUT ALDH1A1 1014/4885MEN1 4333/4885KMT2A 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.